Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Huashi Baidu granules for mild COVID-19 (retrospective cohort)
ChiCTR2200060293Phase 4Not yet recruiting
- Sponsor
- Jiujiang Hospital of Traditional Chinese Medicine
- Start
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of Huashi Baidu Granule in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Jiujiang Hospital of Traditional Chinese Medicine. Primary endpoints: Time to first negative SARS-CoV-2 nucleic acid test and Length of hospitalization. Planned start Apr 2022; status: not yet recruiting.
02
Drugs
Huashi Baidu Granule
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ChiCTR2200060293.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200060293.